Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

NCT ID: NCT03650114

Last Updated: 2025-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

1882 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-28

Study Completion Date

2028-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study.

Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS).

COVID-19 sub-study:

The purpose of this research sub-study is to explore the immune response following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination in a subset of subjects on long-term ofatumumab 20 mg sc. Note: Novartis is not supplying the SARS-CoV-2 vaccine.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Relapsing Multiple Sclerosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

ofatumumab relapsing multiple sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ofatumumab

Subcutaneous injection

Group Type EXPERIMENTAL

Ofatumumab

Intervention Type BIOLOGICAL

subcutaneous injection of 20 mg ofatumumab every 4 weeks

Tetanus toxoid (TT) containing vaccine (Td, Tdap)

Intervention Type BIOLOGICAL

0.5mL Vial/Syringe Containing 5 limit of flocculation (LF) tetanus toxoid

13-valent pneumococcal conjugate vaccine (13-PCV)

Intervention Type BIOLOGICAL

0.5mL Vial/Syringe

23-valent pneumococcal polysaccharide vaccine (23-PPV)

Intervention Type BIOLOGICAL

0.5mL Vial/Syringe

Seasonal Quadrivalent influenza vaccine

Intervention Type BIOLOGICAL

Seasonal 2020-2021 0.5mL Vial/Syringe (trivalent may be used where quadrivalent is not available)

Keyhole limpet hemocyanin (KLH) neo-antigen

Intervention Type BIOLOGICAL

1mg Vial

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ofatumumab

subcutaneous injection of 20 mg ofatumumab every 4 weeks

Intervention Type BIOLOGICAL

Tetanus toxoid (TT) containing vaccine (Td, Tdap)

0.5mL Vial/Syringe Containing 5 limit of flocculation (LF) tetanus toxoid

Intervention Type BIOLOGICAL

13-valent pneumococcal conjugate vaccine (13-PCV)

0.5mL Vial/Syringe

Intervention Type BIOLOGICAL

23-valent pneumococcal polysaccharide vaccine (23-PPV)

0.5mL Vial/Syringe

Intervention Type BIOLOGICAL

Seasonal Quadrivalent influenza vaccine

Seasonal 2020-2021 0.5mL Vial/Syringe (trivalent may be used where quadrivalent is not available)

Intervention Type BIOLOGICAL

Keyhole limpet hemocyanin (KLH) neo-antigen

1mg Vial

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Must have completed a selected Novartis MS study which dosed ofatumumab 20 mg sc every 4 weeks
2. Written informed consent


1. Informed consent
2. Actively enrolled in the COMB157G2399 Study
3. 12 weeks of continuous treatment within the COMB157G2399 Study
4. prior vaccination history as per protocol-defined

Exclusion Criteria

* Emergence of any clinically significant condition/disease during the previous ofatumumab study in which study participation might result in safety risk for the subject
* Subjects with active systemic bacterial, viral or fingal infections, or chronic infection (e.g. AIDS)
* Subjects taking medications prohibited by the protocol

Vaccination sub-study:


* known hypersensitivity or history of systemic allergic, neurologic or other reactions to vaccines
* allergies to egg or shellfish
* any safety findings including low IgG/IgM requiring ofatumumab interruption within 12 weeks prior to vaccination sub-study start
* any major episode of infection requiring hospitalization or treatment with intravenous antibiotics within 2 weeks of the first vaccination sub-study visit
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

North Central Neurology Associates PC

Cullman, Alabama, United States

Site Status

Barrow Neurological Clinics at St Josephs Hospital and MC

Phoenix, Arizona, United States

Site Status

Fullerton Neuro and Headache Ctr

Fullerton, California, United States

Site Status

University of California Davis

Sacramento, California, United States

Site Status

CU Anschutz Med Campus

Aurora, Colorado, United States

Site Status

Mountain Neuro Research Center PC

Basalt, Colorado, United States

Site Status

Alpine Clinical Research Center

Boulder, Colorado, United States

Site Status

Colorado Springs Neurological Associates

Colorado Springs, Colorado, United States

Site Status

Colorado Neurological Research PC

Denver, Colorado, United States

Site Status

University of Colorado Health Neurology

Fort Collins, Colorado, United States

Site Status

Christiana Care Health Services

Newark, Delaware, United States

Site Status

Jem Research Institute

Atlantis, Florida, United States

Site Status

Neurology Offices of South Florida PLLC

Delray Beach, Florida, United States

Site Status

Infinity Clinical Research LLC

Hollywood, Florida, United States

Site Status

Homestead Assoc In Research Inc

Homestead, Florida, United States

Site Status

Neurology Associates PA

Maitland, Florida, United States

Site Status

UM Department Of Neurology

Miami, Florida, United States

Site Status

Aqualane Clinical Research

Naples, Florida, United States

Site Status

MS and Neuromuscular Center of Excellence

Oldsmar, Florida, United States

Site Status

Neurology Associates of Ormond Beach

Ormond Beach, Florida, United States

Site Status

Emerald Coast Neurology

Pensacola, Florida, United States

Site Status

Neurostudies Inc

Port Charlotte, Florida, United States

Site Status

Negroski Neurology

Sarasota, Florida, United States

Site Status

Roskamp Institute Inc

Sarasota, Florida, United States

Site Status

AMO Corporation

Tallahassee, Florida, United States

Site Status

Clinical Research of West Florida Inc

Tampa, Florida, United States

Site Status

Axiom Clinical Research of Florida

Tampa, Florida, United States

Site Status

University Of South Florida

Tampa, Florida, United States

Site Status

Premiere Research Institute

West Palm Beach, Florida, United States

Site Status

Velocity Clinical Research

Savannah, Georgia, United States

Site Status

Georgia Neurology and Sleep Medicine Assoc

Suwanee, Georgia, United States

Site Status

Hawaii Pacific Neuroscience LLC

Honolulu, Hawaii, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

Consultants in Neurology

Northbrook, Illinois, United States

Site Status

Josephson Wallack Munshower Neurology P.C

Indianapolis, Indiana, United States

Site Status

University of Kansas Hospital

Kansas City, Kansas, United States

Site Status

College Park Family Care Center

Overland Park, Kansas, United States

Site Status

Neuro Medical Clinic of Cenla LLC

Alexandria, Louisiana, United States

Site Status

The Neuromedical Center

Baton Rouge, Louisiana, United States

Site Status

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Site Status

Dragonfly Research LLC

Wellesley Hills, Massachusetts, United States

Site Status

Wayne State University Multiple Sclerosis Clinic

Detroit, Michigan, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

Sharlin Health and Neurology

Ozark, Missouri, United States

Site Status

WA Uni School Of Med

St Louis, Missouri, United States

Site Status

Mercy Research

St Louis, Missouri, United States

Site Status

Billings Clinic

Billings, Montana, United States

Site Status

Advanced Neurology Specialists

Great Falls, Montana, United States

Site Status

Cleveland Clinic Foundation

Las Vegas, Nevada, United States

Site Status

University of New Mexico

Albuquerque, New Mexico, United States

Site Status

Ms Ctr Of Northeastern Ny

Latham, New York, United States

Site Status

Asheville Neurology Specialists PA

Asheville, North Carolina, United States

Site Status

The Neurological Institute PA

Charlotte, North Carolina, United States

Site Status

Guilford Neurologic Associate Research

Greensboro, North Carolina, United States

Site Status

Velocity Clinical Research

Raleigh, North Carolina, United States

Site Status

PMG Research of Winston Salem

Winston-Salem, North Carolina, United States

Site Status

Neurology and Neuroscience Assos

Akron, Ohio, United States

Site Status

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status

Ohio Health Research Institute

Columbus, Ohio, United States

Site Status

Columbus Neuroscience

Westerville, Ohio, United States

Site Status

Multiple Sclerosis Center of Excellence of OMRF

Oklahoma City, Oklahoma, United States

Site Status

Providence Neurological Services West

Portland, Oregon, United States

Site Status

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Abington Neurological Associates Ltd

Willow Grove, Pennsylvania, United States

Site Status

Premier Neurology

Greenville, South Carolina, United States

Site Status

BG Neurology

Spartanburg, South Carolina, United States

Site Status

Upstate Clinical Trials LLC

Spartanburg, South Carolina, United States

Site Status

Wesley Neurology Clinic

Cordova, Tennessee, United States

Site Status

Tri State Mountain Neurology

Johnson, Tennessee, United States

Site Status

University of Tennessee Medical Ctr

Knoxville, Tennessee, United States

Site Status

Sibyl Wray MD Neurology PC

Knoxville, Tennessee, United States

Site Status

Med Research Inc

El Paso, Texas, United States

Site Status

Neurology and Sleep Center

Lubbock, Texas, United States

Site Status

Central TX Neuro Consultants P A

Round Rock, Texas, United States

Site Status

Lonestar Neurology of San Antonio

San Antonio, Texas, United States

Site Status

Texas Institute for Neurological Disorders

Sherman, Texas, United States

Site Status

Rocky Mountain MS Clinic

Salt Lake City, Utah, United States

Site Status

The University of Utah

Salt Lake City, Utah, United States

Site Status

Sentara Neuroscience Institute

Virginia Beach, Virginia, United States

Site Status

Evergreen Health Multiple Sclerosis Center

Kirkland, Washington, United States

Site Status

MultiCare Research Institute for Research and Innovation

Tacoma, Washington, United States

Site Status

Aurora BayCare Medical Center

Green Bay, Wisconsin, United States

Site Status

University of Wisconsin Madison

Madison, Wisconsin, United States

Site Status

Ascension St Francis Center

Milwaukee, Wisconsin, United States

Site Status

St Luke s Medical Center Aurora

Milwaukee, Wisconsin, United States

Site Status

Novartis Investigative Site

Rosario, Santa Fe Province, Argentina

Site Status

Novartis Investigative Site

Rosario, Santa Fe Province, Argentina

Site Status

Novartis Investigative Site

Buenos Aires, , Argentina

Site Status

Novartis Investigative Site

Córdoba, , Argentina

Site Status

Novartis Investigative Site

San Miguel de Tucumán, , Argentina

Site Status

Novartis Investigative Site

New Lambton Heights, New South Wales, Australia

Site Status

Novartis Investigative Site

Liverpool, , Australia

Site Status

Novartis Investigative Site

St Leonards, , Australia

Site Status

Novartis Investigative Site

Vienna, Vienna, Austria

Site Status

Novartis Investigative Site

Vienna, , Austria

Site Status

Novartis Investigative Site

Brasschaat, , Belgium

Site Status

Novartis Investigative Site

Bruges, , Belgium

Site Status

Novartis Investigative Site

Brussels, , Belgium

Site Status

Novartis Investigative Site

Edegem, , Belgium

Site Status

Novartis Investigative Site

Ghent, , Belgium

Site Status

Novartis Investigative Site

Sofia, Bulgaria, Bulgaria

Site Status

Novartis Investigative Site

Sofia, Bulgaria, Bulgaria

Site Status

Novartis Investigative Site

Pleven, , Bulgaria

Site Status

Novartis Investigative Site

Sofia, , Bulgaria

Site Status

Novartis Investigative Site

Sofia, , Bulgaria

Site Status

Novartis Investigative Site

London, Ontario, Canada

Site Status

Novartis Investigative Site

Ottawa, Ontario, Canada

Site Status

Novartis Investigative Site

Toronto, Ontario, Canada

Site Status

Novartis Investigative Site

Gatineau, Quebec, Canada

Site Status

Novartis Investigative Site

Greenfield Park, Quebec, Canada

Site Status

Novartis Investigative Site

Montreal, Quebec, Canada

Site Status

Novartis Investigative Site

Québec, Quebec, Canada

Site Status

Novartis Investigative Site

Osijek, , Croatia

Site Status

Novartis Investigative Site

Rijeka, , Croatia

Site Status

Novartis Investigative Site

Zagreb, , Croatia

Site Status

Novartis Investigative Site

Brno, , Czechia

Site Status

Novartis Investigative Site

Havířov, , Czechia

Site Status

Novartis Investigative Site

Hradec Králové, , Czechia

Site Status

Novartis Investigative Site

Jihlava, , Czechia

Site Status

Novartis Investigative Site

Olomouc, , Czechia

Site Status

Novartis Investigative Site

Pardubice, , Czechia

Site Status

Novartis Investigative Site

Prague, , Czechia

Site Status

Novartis Investigative Site

Prague, , Czechia

Site Status

Novartis Investigative Site

Prague, , Czechia

Site Status

Novartis Investigative Site

Prague, , Czechia

Site Status

Novartis Investigative Site

Teplice, , Czechia

Site Status

Novartis Investigative Site

Glostrup Municipality, , Denmark

Site Status

Novartis Investigative Site

Odense C, , Denmark

Site Status

Novartis Investigative Site

Tallinn, , Estonia

Site Status

Novartis Investigative Site

Tartu, , Estonia

Site Status

Novartis Investigative Site

Tampere, , Finland

Site Status

Novartis Investigative Site

Turku, , Finland

Site Status

Novartis Investigative Site

Lille, , France

Site Status

Novartis Investigative Site

Montpellier, , France

Site Status

Novartis Investigative Site

Nantes, , France

Site Status

Novartis Investigative Site

Nice, , France

Site Status

Novartis Investigative Site

Nîmes, , France

Site Status

Novartis Investigative Site

Paris, , France

Site Status

Novartis Investigative Site

Strasbourg, , France

Site Status

Novartis Investigative Site

Munich, Bavaria, Germany

Site Status

Novartis Investigative Site

Neuburg an der Donau, Bavaria, Germany

Site Status

Novartis Investigative Site

Marburg, Hesse, Germany

Site Status

Novartis Investigative Site

Cologne, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Dresden, Saxony, Germany

Site Status

Novartis Investigative Site

Leipzig, Saxony, Germany

Site Status

Novartis Investigative Site

Barsinghausen, , Germany

Site Status

Novartis Investigative Site

Bayreuth, , Germany

Site Status

Novartis Investigative Site

Bielefeld, , Germany

Site Status

Novartis Investigative Site

Bochum, , Germany

Site Status

Novartis Investigative Site

Essen, , Germany

Site Status

Novartis Investigative Site

Hamburg, , Germany

Site Status

Novartis Investigative Site

Hanover, , Germany

Site Status

Novartis Investigative Site

Heidelberg, , Germany

Site Status

Novartis Investigative Site

Minden, , Germany

Site Status

Novartis Investigative Site

München, , Germany

Site Status

Novartis Investigative Site

Potsdam, , Germany

Site Status

Novartis Investigative Site

Siegen, , Germany

Site Status

Novartis Investigative Site

Ulm, , Germany

Site Status

Novartis Investigative Site

Unterhaching, , Germany

Site Status

Novartis Investigative Site

Athens, , Greece

Site Status

Novartis Investigative Site

Thessaloniki, , Greece

Site Status

Novartis Investigative Site

Budapest, HUN, Hungary

Site Status

Novartis Investigative Site

Budapest, , Hungary

Site Status

Novartis Investigative Site

Budapest, , Hungary

Site Status

Novartis Investigative Site

Budapest, , Hungary

Site Status

Novartis Investigative Site

Kistarcsa, , Hungary

Site Status

Novartis Investigative Site

Pécs, , Hungary

Site Status

Novartis Investigative Site

Szeged, , Hungary

Site Status

Novartis Investigative Site

Kochi, Kerala, India

Site Status

Novartis Investigative Site

Mumbai, Maharashtra, India

Site Status

Novartis Investigative Site

Pune, Maharashtra, India

Site Status

Novartis Investigative Site

New Delhi, National Capital Territory of Delhi, India

Site Status

Novartis Investigative Site

New Delhi, National Capital Territory of Delhi, India

Site Status

Novartis Investigative Site

Chandigarh, Punjab, India

Site Status

Novartis Investigative Site

Hyderabad, Telangana, India

Site Status

Novartis Investigative Site

Howrah, West Bengal, India

Site Status

Novartis Investigative Site

Mangalore, , India

Site Status

Novartis Investigative Site

Ashkelon, , Israel

Site Status

Novartis Investigative Site

Haifa, , Israel

Site Status

Novartis Investigative Site

Sefad, , Israel

Site Status

Novartis Investigative Site

Tel Aviv, , Israel

Site Status

Novartis Investigative Site

Chiba, Chiba, Japan

Site Status

Novartis Investigative Site

Tōon, Ehime, Japan

Site Status

Novartis Investigative Site

Sapporo, Hokkaido, Japan

Site Status

Novartis Investigative Site

Morioka, Iwate, Japan

Site Status

Novartis Investigative Site

Sendai, Miyagi, Japan

Site Status

Novartis Investigative Site

Sendai, Miyagi, Japan

Site Status

Novartis Investigative Site

Kawagoe, Saitama, Japan

Site Status

Novartis Investigative Site

Kodaira, Tokyo, Japan

Site Status

Novartis Investigative Site

Shinjuku-ku, Tokyo, Japan

Site Status

Novartis Investigative Site

Niigata, , Japan

Site Status

Novartis Investigative Site

Osaka, , Japan

Site Status

Novartis Investigative Site

Riga, LV, Latvia

Site Status

Novartis Investigative Site

Riga, , Latvia

Site Status

Novartis Investigative Site

Riga, , Latvia

Site Status

Novartis Investigative Site

Kaunas, LTU, Lithuania

Site Status

Novartis Investigative Site

Vilnius, , Lithuania

Site Status

Novartis Investigative Site

Mexico City, Mexico City, Mexico

Site Status

Novartis Investigative Site

Mexico City, Mexico City, Mexico

Site Status

Novartis Investigative Site

Chihuahua City, , Mexico

Site Status

Novartis Investigative Site

Sittard-Geleen, Limburg, Netherlands

Site Status

Novartis Investigative Site

Amsterdam, North Holland, Netherlands

Site Status

Novartis Investigative Site

Rotterdam, South Holland, Netherlands

Site Status

Novartis Investigative Site

Drammen, , Norway

Site Status

Novartis Investigative Site

Lima Cercado, Lima region, Peru

Site Status

Novartis Investigative Site

San Isidro, Lima region, Peru

Site Status

Novartis Investigative Site

Lima, , Peru

Site Status

Novartis Investigative Site

Bydgoszcz, Woj Kujawsko Pomorskie, Poland

Site Status

Novartis Investigative Site

Gdansk, , Poland

Site Status

Novartis Investigative Site

Gdansk, , Poland

Site Status

Novartis Investigative Site

Glogow Wielkopolski, , Poland

Site Status

Novartis Investigative Site

Katowice, , Poland

Site Status

Novartis Investigative Site

Kielce, , Poland

Site Status

Novartis Investigative Site

Lodz, , Poland

Site Status

Novartis Investigative Site

Poznan, , Poland

Site Status

Novartis Investigative Site

Rzeszów, , Poland

Site Status

Novartis Investigative Site

Warsaw, , Poland

Site Status

Novartis Investigative Site

Wroclaw, , Poland

Site Status

Novartis Investigative Site

Zabrze, , Poland

Site Status

Novartis Investigative Site

Braga, , Portugal

Site Status

Novartis Investigative Site

Coimbra, , Portugal

Site Status

Novartis Investigative Site

Lisbon, , Portugal

Site Status

Novartis Investigative Site

Lisbon, , Portugal

Site Status

Novartis Investigative Site

Loures, , Portugal

Site Status

Novartis Investigative Site

Matosinhos Municipality, , Portugal

Site Status

Novartis Investigative Site

Porto, , Portugal

Site Status

Novartis Investigative Site

Santa Maria da Feira, , Portugal

Site Status

Novartis Investigative Site

Kazan', , Russia

Site Status

Novartis Investigative Site

Kemerovo, , Russia

Site Status

Novartis Investigative Site

Krasnoyarsk, , Russia

Site Status

Novartis Investigative Site

Moscow, , Russia

Site Status

Novartis Investigative Site

Moscow, , Russia

Site Status

Novartis Investigative Site

Nizhny Novgorod, , Russia

Site Status

Novartis Investigative Site

Nizhny Novgorod, , Russia

Site Status

Novartis Investigative Site

Novosibirsk, , Russia

Site Status

Novartis Investigative Site

Novosibirsk, , Russia

Site Status

Novartis Investigative Site

Saint Petersburg, , Russia

Site Status

Novartis Investigative Site

Saint Petersburg, , Russia

Site Status

Novartis Investigative Site

Saint Petersburg, , Russia

Site Status

Novartis Investigative Site

Saint Petersburg, , Russia

Site Status

Novartis Investigative Site

Saransk, , Russia

Site Status

Novartis Investigative Site

Sestroretsk, , Russia

Site Status

Novartis Investigative Site

Tyumen, , Russia

Site Status

Novartis Investigative Site

Yekaterinburg, , Russia

Site Status

Novartis Investigative Site

Banská Bystrica, Slovakia, Slovakia

Site Status

Novartis Investigative Site

Bratislava, Slovakia, Slovakia

Site Status

Novartis Investigative Site

Bratislava, Slovakia, Slovakia

Site Status

Novartis Investigative Site

Bratislava, Slovakia, Slovakia

Site Status

Novartis Investigative Site

Martin, Slovakia, Slovakia

Site Status

Novartis Investigative Site

Nitra, Slovakia, Slovakia

Site Status

Novartis Investigative Site

Trnava, Slovakia, Slovakia

Site Status

Novartis Investigative Site

Pretoria, , South Africa

Site Status

Novartis Investigative Site

Rosebank, , South Africa

Site Status

Novartis Investigative Site

Cadiz, Andalusia, Spain

Site Status

Novartis Investigative Site

Seville, Andalusia, Spain

Site Status

Novartis Investigative Site

L'Hospitalet de Llobregat, Barcelona, Spain

Site Status

Novartis Investigative Site

Donostia / San Sebastian, Basque Country, Spain

Site Status

Novartis Investigative Site

Barcelona, Catalonia, Spain

Site Status

Novartis Investigative Site

Barcelona, Catalonia, Spain

Site Status

Novartis Investigative Site

Salt, Girona, Spain

Site Status

Novartis Investigative Site

Majadahonda, Madrid, Spain

Site Status

Novartis Investigative Site

Pozuelo de Alarcón, Madrid, Spain

Site Status

Novartis Investigative Site

El Palmar, Murcia, Spain

Site Status

Novartis Investigative Site

Castilleja de la Cuesta, Sevilla, Spain

Site Status

Novartis Investigative Site

Barakaldo, Vizcaya, Spain

Site Status

Novartis Investigative Site

Barcelona, , Spain

Site Status

Novartis Investigative Site

Barcelona, , Spain

Site Status

Novartis Investigative Site

Madrid, , Spain

Site Status

Novartis Investigative Site

Madrid, , Spain

Site Status

Novartis Investigative Site

Madrid, , Spain

Site Status

Novartis Investigative Site

Málaga, , Spain

Site Status

Novartis Investigative Site

Valencia, , Spain

Site Status

Novartis Investigative Site

Gothenburg, , Sweden

Site Status

Novartis Investigative Site

Stockholm, , Sweden

Site Status

Novartis Investigative Site

Basel, , Switzerland

Site Status

Novartis Investigative Site

Lugano, , Switzerland

Site Status

Novartis Investigative Site

Tainan, , Taiwan

Site Status

Novartis Investigative Site

Khon Kaen, THA, Thailand

Site Status

Novartis Investigative Site

Samsun, Atakum, Turkey (Türkiye)

Site Status

Novartis Investigative Site

Istanbul, Bakirkoy, Turkey (Türkiye)

Site Status

Novartis Investigative Site

Izmir, Balcova, Turkey (Türkiye)

Site Status

Novartis Investigative Site

Istanbul, Fatih, Turkey (Türkiye)

Site Status

Novartis Investigative Site

Izmir, Karsiyaka, Turkey (Türkiye)

Site Status

Novartis Investigative Site

Köseköy, Kocaeli, Turkey (Türkiye)

Site Status

Novartis Investigative Site

Trabzon, Ortahisar, Turkey (Türkiye)

Site Status

Novartis Investigative Site

Istanbul, Sancaktepe, Turkey (Türkiye)

Site Status

Novartis Investigative Site

Istanbul, Sultangazi, Turkey (Türkiye)

Site Status

Novartis Investigative Site

Mersin, Yenisehir, Turkey (Türkiye)

Site Status

Novartis Investigative Site

Izmir, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Luton, Beds, United Kingdom

Site Status

Novartis Investigative Site

Glasgow, Scotland, United Kingdom

Site Status

Novartis Investigative Site

Sheffield, South Yorkshire, United Kingdom

Site Status

Novartis Investigative Site

London, , United Kingdom

Site Status

Novartis Investigative Site

London, , United Kingdom

Site Status

Novartis Investigative Site

Oxford, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Belgium Bulgaria Canada Croatia Czechia Denmark Estonia Finland France Germany Greece Hungary India Israel Japan Latvia Lithuania Mexico Netherlands Norway Peru Poland Portugal Russia Slovakia South Africa Spain Sweden Switzerland Taiwan Thailand Turkey (Türkiye) United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Hauser SL, Cohen JA, de Seze J, Meuth SG, Giacomini PS, Nakahara J, Oreja-Guevara C, Robertson D, Wray S, Bhatt A, Hu X, Xi J, Piccolo R, Jehl V, Sullivan R, Boer I, Wiendl H, Kappos L. Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis. Neurol Ther. 2025 Oct;14(5):1975-1992. doi: 10.1007/s40120-025-00784-0. Epub 2025 Jul 13.

Reference Type DERIVED
PMID: 40652442 (View on PubMed)

Hauser SL, Zielman R, Das Gupta A, Xi J, Stoneman D, Karlsson G, Robertson D, Cohen JA, Kappos L. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension. Mult Scler. 2023 Oct;29(11-12):1452-1464. doi: 10.1177/13524585231195346. Epub 2023 Sep 11.

Reference Type DERIVED
PMID: 37691530 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COMB157G2399

Identifier Type: -

Identifier Source: org_study_id